Format

Send to

Choose Destination
See comment in PubMed Commons below
Rheumatol Int. 2002 Nov;22(6):227-32. Epub 2002 Sep 4.

Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab.

Author information

1
Department of Internal Medicine V, Department of Rheumatology, Wilhelminenspital, Montleartstrasse 37, 1160 Vienna, Austria. edmund.cauza@akh-wien.ac.at

Abstract

OBJECTIVE:

The aim was to evaluate the efficacy and safety of multiple infusions with achimeric, anti-tumor necrosis factor (TNF)alpha monoclonal antibody (infliximab) in patients with psoriatic arthritis (PsA) and psoriasis vulgaris.

METHODS:

Over 22 weeks, nine patients with both active psoriasis and PsA received five infusions of 3 mg/kg infliximab. The endpoints included changes in the swollen and tender joints counts, American College of Rheumatology (ACR) preliminary criteria for improvement response rates 20, 50, and 70, and improvement in the psoriasis area and severity index (PASI).

RESULTS:

The swollen count (SJC) and tender joint count (TJC) fell from means of 5.33+/-2.22 and 17.80+/-4.21 to 1.44+/-1.09 and 9.77+/-0.92, respectively, by week 2 ( P=0.02, P=0.02). This benefit was sustained through week 22 (2.00+/-1.12/7.77+/-3.68, P=0.05/ P=0.002). The ACR 20/50/70 response was achieved in 89%/56%/22% of cases. The mean PASI score improved from 19.04+/-5.41 to 4.91+/-2.51 ( P=0.002).

CONCLUSION:

Multiple infusions of infliximab were effective and well tolerated in patients with active psoriasis and PsA.

PMID:
12426660
DOI:
10.1007/s00296-002-0246-3
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center